

---

## Overview

### Useful For

Aiding in the distinction between the myeloproliferative neoplasm polycythemia vera (PV) and other secondary erythrocytosis

Evaluating for mutations within exons 12 to 15 of *JAK2* in an algorithmic process as part of PVJAK / Polycythemia Vera, *JAK2* V617F with Reflex to *JAK2* Exon 12-15, Sequencing for Erythrocytosis, Varies

### Method Name

Only orderable as a reflex. For more information, see PVJAK / Polycythemia Vera, *JAK2* V617F with Reflex to *JAK2* Exon 12-15, Sequencing for Erythrocytosis, Varies.

Sanger Sequencing

### NY State Available

Yes

## Specimen

### Specimen Type

Varies

### Specimen Required

Only orderable as a reflex. For more information, see PVJAK / Polycythemia Vera, *JAK2* V617F with Reflex to *JAK2* Exon 12-15, Sequencing for Erythrocytosis, Varies.

### Submit only 1 of the following specimens:

**Specimen Type:** Blood

**Container/Tube:** Lavender top (EDTA) or yellow top (ACD-B)

**Specimen Volume:** 10 mL

#### Collection Instructions:

1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. **Do not aliquot.**
3. Label specimen as blood.

**Specimen Type:** Bone marrow aspirate

**Container/Tube:** Lavender top (EDTA) or yellow top (ACD-B)

**Specimen Volume:** 4 mL

**Collection Instructions:**

1. Invert several times to mix blood.
2. Send bone marrow specimen in original tube. **Do not aliquot.**
3. Label specimen as bone marrow.

**Specimen Minimum Volume**

Whole blood: 8 mL; Bone marrow: 2 mL

**Reject Due To**

Gross hemolysis	Reject
Paraffin-embedded bone marrow aspirate clot or biopsy blocks	Reject
Slides	Reject
Paraffin shavings	Reject
Moderately to severely clotted	Reject

**Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Varies	Refrigerated (preferred)	5 days	
	Ambient	5 days	

**Clinical & Interpretive**
**Clinical Information**

The Janus kinase 2 (*JAK2*) gene codes for a tyrosine kinase (*JAK2*) that is associated with the cytoplasmic portion of a variety of transmembrane cytokine and growth factor receptors important for signal transduction in hematopoietic cells. Signaling via *JAK2* activation causes phosphorylation of downstream signal transducers and activators of transcription (STAT) proteins (eg, STAT5) ultimately leading to cell growth and differentiation. The *JAK2* V617F is located in exon 14 and present in 50% to 60% of primary myelofibrosis and essential thrombocythemia, and 95% to 98% of polycythemia vera (PV). In the rest of the PV cases, over 50 different mutations have been reported within exons 12 through 15 of *JAK2* and essentially all of the non-V617F *JAK2* mutations have been identified in PV. These mutations include point alterations and small insertions or deletions. Several of the exon 12 mutations have been shown to have biologic effects similar to those caused by the V617F mutation such that it is currently assumed other nonpolymorphic mutations have similar clinical effects. However, some mutations may not be well characterized and require further clinical and research

---

evaluation.

**Reference Values**

Only orderable as a reflex. For more information, see PVJAK / Polycythemia Vera, *JAK2* V617F with Reflex to *JAK2* Exon 12-15, Sequencing for Erythrocytosis, Varies.

An interpretive report will be provided.

**Interpretation**

The results will be reported as 1 of the 3 following states:

- Positive for *JAK2* V617F mutation
- Positive for *JAK2* mutation (other than V617F)
- Negative for *JAK2* mutations

If the result is positive, a description of the mutation at the nucleotide level and the altered protein sequence are reported.

A positive mutation status is highly suggestive of a myeloid neoplasm and may support a diagnosis of polycythemia vera in the appropriate clinical setting. Correlation with clinicopathologic findings and other laboratory results is necessary in all cases.

A negative mutation status makes a diagnosis of polycythemia vera highly unlikely, although it does not completely exclude this possibility, other myeloproliferative neoplasms, or other neoplasms.

**Cautions**

A positive result is not specific for a particular diagnosis. Correlation with clinicopathologic findings and other laboratory results is necessary in all cases.

If this test is ordered in the setting of erythrocytosis and suspicion of polycythemia vera, interpretation requires correlation with a concurrent or recent prior bone marrow evaluation.

**Clinical Reference**

1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase *JAK2* in human myeloproliferative disorders. *Lancet*. 2005;365(9464):1054-1061
2. James C, Ugo V, Le Couedic JP, et al. A unique clonal *JAK2* mutation leading to constitutive signaling causes polycythaemia vera. *Nature*. 2005;434(7037):1144-1148
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of *JAK2* in myeloproliferative disorders. *N Engl J Med*. 2005;352:1779-1790
4. Steensma DP, Dewald GW, Lasho TL, et al. The *JAK2* V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and the myelodysplastic syndrome. *Blood*. 2005;106:1207-1209
5. Ma W, Kantarjian H, Zhang X, et al. Mutation profile of *JAK2* transcripts in patients with chronic myeloid neoplasias. *J Mol Diagn*. 2009;11:49-53
6. Kilpivaara O, Levine RL. *JAK2* and *MPL* mutations in myeloproliferative neoplasms: discovery and science. *Leukemia*. 2008;22:1813-1817
7. Kravolics R. Genetic complexity of myeloproliferative neoplasms. *Leukemia*. 2008;22:1841-1848

8. Defour JP, Chachoua I, Pecquet C, Constantinescu SN. Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms. *Leukemia*. 2016;30:1214-1216.

doi:10.1038/leu.2015.271

9. Tefferi A. The classic myeloproliferative neoplasms: Chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, and primary myelofibrosis. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, eds. *The Online Metabolic and Molecular Bases of Inherited Disease*. McGraw-Hill; 2019. Accessed February 25, 2026. Available at <https://ommbid.mhmedical.com/content.aspx?sectionid=225078035&bookid=2709>

## Performance

### Method Description

For the Sanger sequencing, total RNA is extracted from whole blood/bone marrow and complementary DNA synthesized from *JAK2* messenger RNA. A fragment spanning exons 12 through 15 is then amplified using standard polymerase chain reaction and the sequence is obtained using Sanger sequencing with analysis on an automated genetic analyzer. (Unpublished Mayo method)

### PDF Report

No

### Day(s) Performed

Monday through Saturday

### Report Available

7 to 10 days

### Specimen Retention Time

Whole blood/Bone marrow: 2 weeks; Extracted RNA: 3 months

### Performing Laboratory Location

Mayo Clinic Laboratories - Rochester Main Campus

## Fees & Codes

### Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

### Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

0027U-JAK2 (Janus kinase 2) (eg, myeloproliferative disorder), exon 12 sequence and exon 13 sequence, if performed